The DOI matches its Crossref record.
Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
Open accessAbstract
Dengue is caused by four serotype-distinct dengue viruses (DENVs), and developing a multivalent vaccine against dengue has not been straightforward since partial immunity to DENV may predispose to more severe disease upon subsequent DENV infection. The vaccine that is furthest along in development is CYD™, a live attenuated tetravalent vaccine (LATV) produced by Sanofi Pasteur. Although the multi-dose vaccine demonstrated protection against severe dengue, its overall efficacy was limited by DENV serotype, serostatus at vaccination, region and age. The National Institute of Allergy and Infectious Diseases has developed the LATV dengue vaccines TV003/TV005. A single dose of either TV003 or TV005 induced seroconversion to four DENV serotypes in 74-92% (TV003) and 90% (TV005) of flavivirus seronegative adults and elicited near-sterilizing immunity to a second dose of vaccine administered 6-12 months later. The important differences in the structure, infectivity and immune responses to TV003/TV005 are compared with CYD™.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The continued threat of emerging flaviviruses
Pierson, T. C., & Diamond, M. S. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0714-0 · Cited by 1,098
Wilder-Smith, A., Ooi, E.-E., Horstick, O., & Wills, B. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32560-1 · Cited by 692
Dengue virus: epidemiology, biology, and disease aetiology
Roy, S. K., & Bhattacharjee, S. (2021) · Canadian Journal of Microbiology · doi:10.1139/cjm-2020-0572 · Cited by 440
Dengue Fever: Causes, Complications, and Vaccine Strategies
Khetarpal, N., & Khanna, I. (2016) · Journal of Immunology Research · doi:10.1155/2016/6803098 · Cited by 363
Paz-Bailey, G., Adams, L. E., Deen, J., Anderson, K. B., & Katzelnick, L. C. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02576-x · Cited by 346
Metadata
- Authors
- Whitehead, S. S.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2015-12-02
- Volume
- 15
- Issue
- 4
- Pages
- 509-517
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2192317075
- Cited by
- 176
- References
- 0
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? https://app.cochat.ai/papers/10.1586/14760584.2016.1115727
- The paper
- Whitehead, S. S. (2016). Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? Expert Review of Vaccines. https://doi.org/10.1586/14760584.2016.1115727
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.